4//SEC Filing
Batycky Alka 4
Accession 0001415889-24-014338
CIK 0001785345other
Filed
May 22, 8:00 PM ET
Accepted
May 23, 5:45 PM ET
Size
6.3 KB
Accession
0001415889-24-014338
Insider Transaction Report
Form 4
Batycky Alka
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2024-05-23−3,600→ 0 totalExercise: $3.05→ Common Stock (3,600 underlying)
Footnotes (1)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 ("Merger Agmt"), by and among the Issuer, AbbVie Inc. ("Guarantor"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor ("Parent") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger ("Effective Time"), this option was canceled and converted into the right to receive (a) a cash amount equal to (1) the number of shares underlying this option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this option, plus (b) one contractual contingent value right representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes.
Documents
Issuer
Landos Biopharma, Inc.
CIK 0001785345
Entity typeother
Related Parties
1- filerCIK 0001978041
Filing Metadata
- Form type
- 4
- Filed
- May 22, 8:00 PM ET
- Accepted
- May 23, 5:45 PM ET
- Size
- 6.3 KB